Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials
Eur Urol
.
2024 Oct;86(4):369-371.
doi: 10.1016/j.eururo.2024.06.019.
Epub 2024 Jul 17.
Authors
Daniel E Spratt
1
,
Vinnie Y T Liu
2
,
Angela Y Jia
3
,
Trevor J Royce
2
,
Howard M Sandler
4
,
Stephanie L Pugh
5
,
Phuoc T Tran
6
,
Felix Y Feng
7
Affiliations
1
University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. Electronic address: daniel.spratt@uhhospitals.org.
2
Artera Inc., Los Altos, CA, USA.
3
University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
4
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
5
NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; American College of Radiology, Philadelphia, PA, USA.
6
University of Maryland/Greenebaum Cancer Center, Baltimore, MD, USA.
7
University of California-San Francisco, San Francisco, CA, USA.
PMID:
39025748
PMCID:
PMC11480946
DOI:
10.1016/j.eururo.2024.06.019
No abstract available
Publication types
Meta-Analysis
MeSH terms
Artificial Intelligence*
Biomarkers, Tumor
Clinical Trials, Phase III as Topic
Humans
Male
Prostatic Neoplasms* / pathology
Randomized Controlled Trials as Topic*
Risk Assessment
Risk Factors
Substances
Biomarkers, Tumor
Grants and funding
UG1 CA189867/CA/NCI NIH HHS/United States
R21 CA274500/CA/NCI NIH HHS/United States
R01 CA271540/CA/NCI NIH HHS/United States
U01 CA231776/CA/NCI NIH HHS/United States
U24 CA196067/CA/NCI NIH HHS/United States
U01 CA212007/CA/NCI NIH HHS/United States
U01 CA257638/CA/NCI NIH HHS/United States
U10 CA180822/CA/NCI NIH HHS/United States
U10 CA180868/CA/NCI NIH HHS/United States
U54 CA273956/CA/NCI NIH HHS/United States